Privately held biotechnology company developing EDI200, a recombinant ectodysplasin-A1 replacement protein intended to treat X-linked hypohidrotic ectodermal dysplasia (XLHED), a rare genetic developmental disorder
Privately held biotechnology company developing EDI200, a recombinant ectodysplasin-A1 replacement protein intended to treat X-linked hypohidrotic ectodermal dysplasia (XLHED), a rare genetic developmental disorder.